Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
16-week randomized, double-blind trial of oral UT-15C SR added to ERA and/or PDE5 inhibitor in pulmonary arterial hypertension
2006-000800-17Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Nov 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) comparing UT-15C SR arm with Placebo arm (2 arms). Primary endpoint: Change in 6-minute walk distance from baseline to week 16. Started Nov 2006; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2006-000800-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000800-17.